An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Department of Health (1999) Faster Access to Modern Treatment: How NICE Appraisal Will Work.Leeds: NHS Executive.Google Scholar
Donoghue, J., Tylee, A. & Wildgust, H. (1996) Cross-sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993–95. British Medical Journal, 313, 861862Google Scholar
Drummond, M. & Aristides, M. (1997) The Australian cost effectiveness guidelines: An update. In Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK Learn from Australia and Canada? (ed. Towse, A.), pp. 616. London: Office of Health Economics.Google Scholar
Effective Health Care (1993) The Management of Depression in Primary Care.Volume 1, Bulletin No 5, York: University of York.Google Scholar
Effective Health Care (1997) Mental Health Promotion in High Risk Groups.Volume 3, Bulletin No 3. York: University of York.Google Scholar
Hotopf, M. H., Lewis, G. & Normand, C. (1997) Putting trials on trial – the costs and consequences of small trials in depression: a systematic review of methodology. Journal of Epidemiology and Community Health, 51, 354358.Google Scholar
Kendell, R. E. (1999) Influencing the Department of Health. Psychiatric Bulletin, 23, 321323.Google Scholar
Lewis, G. (1997) Closing the gap between research and practice. New evidence is required. British Journal of Psychiatry, 171, 227Google Scholar
Mari, J. J. & Streiner, D. (1998) Family intervention for those with schizophrenia.In The Cochrane Library, Issue 4.Oxford: Update Software.Google Scholar
Marshall, M. & Lockwood, A. (1998) Assertive community treatment for people with severe mental disorders.In The Cochrane Library, Issue 4.Oxford: Update Software.Google Scholar
Maynard, A. & Bloor, K. (1998) Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals. British Journal of Psychiatry, 173 (suppl. 36), 1218Google Scholar
Melzer, D. (1998) New drug treatment for Alzheimer's disease: lessons for healthcare policy. British Medical Journal316, 762764Google Scholar
NHS Management Executive (1994) Prescribing Expenditure: Guidance on Allocations and Budget Setting 1994/5. EL (94) 2. Leeds: Department of Health.Google Scholar
Rawlins, M. (1999) In pursuit of excellence: the National Institute of Clinical Excellence. Lancet, 353, 10791082Google Scholar
Secretary of State for Health (1998a) A First Class Service: Quality in the New NHS.London: HMSO.Google Scholar
Secretary of State for Health (1998b) Modernising Mental Health Services: Safe, Sound and Supportive.London: HMSO.Google Scholar
Sheldon, T. A. & Faulkner, A. (1996) Vetting new technologies. British Medical Journal313, 508.CrossRefGoogle ScholarPubMed
Thornley, B. & Adams, C. E. (1998) Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal311, 18811884.Google Scholar
Vaughan, P. J. (1998) Supervision register in practice. Psychiatric Bulletin, 22, 412415.Google Scholar
eLetters
No eLetters have been published for this article.